Shares of ReWalk Robotics Ltd. (NASDAQ:RWLK) saw an uptick in trading volume on Tuesday . 299,208 shares were traded during mid-day trading, an increase of 234% from the previous session’s volume of 89,575 shares.The stock last traded at $6.56 and had previously closed at $6.47.

Several research firms recently weighed in on RWLK. Jefferies Group restated a “buy” rating and issued a $16.00 price objective on shares of ReWalk Robotics in a research report on Sunday, May 8th. Zacks Investment Research lowered ReWalk Robotics from a “buy” rating to a “hold” rating in a research note on Thursday, July 7th. Piper Jaffray Cos. initiated coverage on ReWalk Robotics in a research note on Friday, July 15th. They issued an “overweight” rating and a $10.00 target price for the company. Finally, Canaccord Genuity reaffirmed a “buy” rating on shares of ReWalk Robotics in a research note on Sunday. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $12.80.

The company’s market capitalization is $83.14 million. The firm’s 50 day moving average price is $6.69 and its 200-day moving average price is $8.48.

ReWalk Robotics (NASDAQ:RWLK) last posted its quarterly earnings data on Thursday, August 4th. The medical device company reported ($0.64) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.53) by $0.11. The firm earned $0.82 million during the quarter, compared to analysts’ expectations of $1.95 million. The business’s revenue was up 34.4% compared to the same quarter last year. On average, equities research analysts forecast that ReWalk Robotics Ltd. will post ($2.18) EPS for the current year.

In related news, major shareholder Scp Vitalife Partners (Israel) sold 4,043 shares of ReWalk Robotics stock in a transaction that occurred on Friday, May 20th. The stock was sold at an average price of $9.09, for a total transaction of $36,750.87. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Jeff Dykan sold 27,022 shares of ReWalk Robotics stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $8.69, for a total value of $234,821.18. The disclosure for this sale can be found here.

ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow wheelchair-bound individuals with mobility impairments or other medical conditions the ability to stand and walk. The Company offers ReWalk, an exoskeleton that uses its tilt-sensor technology, and an on-board computer and motion sensors to drive motorized legs that power movement.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.